CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC)

Subjects

Subjects :

0301 basic medicine
Oncology
medicine.medical_specialty
Chemotherapy
business.industry
medicine.medical_treatment
non-small cell lung cancer (NSCLC)
Ipilimumab
Hematology
medicine.disease
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Internal medicine
medicine
Nivolumab
Open label
business
Chemotherapy naive
030215 immunology
medicine.drug

Details

ISSN :

09237534

Volume :

28

Database :

OpenAIRE

Journal :

Annals of Oncology

Accession number :

edsair.doi...........c4e06591e4abee4993eb8f9035359790

Full Text :

https://doi.org/10.1093/annonc/mdx091.064